White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Eduardo Bolsonaro Granted U.S. Green Card Amid Brazil Legal Battle and Tariff Dispute 
DOJ Subpoenas New York Times Freelancer Over North Korea Military Report 
Trump Administration Releases New UFO Files and Apollo Mission Records 
Maduro U.S. Drug Trafficking Trial Set for June 2027 as Immunity Defense Looms 
US Judge Dismisses Gautam Adani Criminal Charges 
US Dollar Near Two-Month Low as Markets Await Inflation Data 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
US Yen Intervention Unlikely to Deliver Lasting Recovery, Yardeni Says 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
